Therapeutic potential of mature adipocyte-derived dedifferentiated fat cells for inflammatory bowel disease
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · May 2020 · 1 min read
In brief
In brief
Study demonstrates that dedifferentiated fat (DFAT) cells derived from mature adipocytes suppress T cell proliferation and improve clinical outcomes in a mouse IBD model. DFAT cell transplantation reduced weight loss and colon damage through immunoregulatory mechanisms involving TRAIL, IDO1, and NOS2 pathways.
Written by the GCMD Library team from the article.
Abstract
Purpose
Our previous studies demonstrated that mature adipocyte-derived dedifferentiated fat (DFAT) cells possess similar multipotency as mesenchymal stem cells. Here, we examined the immunoregulatory potential of DFAT cells in vitro and the therapeutic effect of DFAT cell transplantation in a mouse inflammatory bowel disease (IBD) model.
Methods
The effect of DFAT cell co-culture on T cell proliferation and expression of immunosuppression-related genes in DFAT cells were evaluated. To create IBD, CD4+CD45RBhigh T cells were intraperitoneally injected into SCID mice. One week later, DFAT cells (1 × 105, DFAT group) or saline (Control group) were intraperitoneally injected. Subsequently bodyweight was measured every week and IBD clinical and histological scores were evaluated at 5 weeks after T cell administration.
Results
The T cell proliferation was inhibited by co-cultured DFAT cells in a cell density-dependent manner. Gene expression of TRAIL, IDO1, and NOS2 in DFAT cells was upregulated by TNFα stimulation. DFAT group improved IBD-associated weight loss, IBD clinical and histological scores compared to Control group.
Conclusion
DFAT cells possess immunoregulatory potential and the cell transplantation promoted recovery from colon damage and improved clinical symptoms in the IBD model. DFAT cells could play an important role in the treatment of IBD.